NA
AVXL icon

NewEdge Advisors’s Anavex Life Sciences AVXL Stock Holding History

NewEdge Advisors’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$113K Buy
36,733
+8,502
+30% +$36.8K ﹤0.01% 2723
2025
Q4 		$101K Buy
28,231
+26,605
+1,636% +$163K ﹤0.01% 2760
2025
Q3 		$14.5K Hold
1,626
– – ﹤0.01% 3228
2025
Q2 		$15K Buy
+1,626
New +$13.9K ﹤0.01% 3048
2023
Q1 		– Sell
-140
Closed -$1.3K – 3466
2022
Q4 		$1.3K Buy
+140
New +$1.5K ﹤0.01% 2957

Other funds holding AVXL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SF
Summit Financial Parsippany, New Jersey $7.85B AUM 20.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

NewEdge Advisors's AVXL Position: Q1 2026 in Review

NewEdge Advisors increased its Anavex Life Sciences (AVXL) stake by 30% in Q1 2026, buying an estimated $36.8K and bringing the position to 36,733 shares worth $113K. The position accounts for ﹤0.01% of the portfolio, ranked #2723.

NewEdge Advisors first reported a position in AVXL in Q4 2022 and has held it in 5 quarters since. 190 funds tracked by Wall St. Rank hold AVXL as of Q1 2026.

  • NewEdge Advisors held 36,733 shares of Anavex Life Sciences worth $113K as of Q1 2026.
  • NewEdge Advisors bought 8,502 Anavex Life Sciences shares in Q1 2026, an estimated $36.8K.
  • Anavex Life Sciences made up ﹤0.01% of NewEdge Advisors's portfolio in Q1 2026, its #2723 holding.
  • NewEdge Advisors first reported a position in Anavex Life Sciences in Q4 2022 and has held it in 5 quarters since.
  • 190 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.